This report has been superceded by the newest report on Tissue Engineering, Cell Therapy &
Transplantation. Click here.
Engineering, Cell Therapy and Transplantation: Products, Technologies & Market Opportunities, 2003-2013
338 pages ·
32 Exhibits ·
176 Company Profiles ·
Pub. Date August 2003 ·
report examines the status of technologies, applications and markets for
tissue engineering. The report reviews therapeutic technologies under
various stages of development at over 150 companies. Products being
developed address major causes of death and disease spanning applications
in cardiovascular, neurological, orthopaedic, skin, organ and others. The
report details the status of product development and assesses the current
and forecast market for tissue engineering and transplantation products.
Table of Contents
1.3 History of Tissue Reconstruction and Engineering
1.4 Growth of Key Procedures
1.5 Evolution of Tissue Processing Corporations
1.6 Regulatory Controls Shaping the Industry
1.7 Tissue Engineering as a Solution
1.8 Development Challenges
1.8.1 Material Based Tissue Replacements
1.8.2 Allograft Derived Tissue Replacements
1.8.3 Cell and Tissue Engineered Products
1.9 Market Expectations for Tissue Reconstruction and Engineering
1.9.1 Material Based Tissue Replacements
1.9.2 Allograft Tissue Replacements
1.9.3 Cell and Tissue Engineered Replacements
1.10 Unmet Clinical Need
1.11 Developing Tissue-Engineered Products
1.11.1 Culturing Cells
1.11.2 Cell Delivery
1.11.3 Bioengineering Cells and Tissues
1.12 Autologous, Allogeneic, and Xenogeneic Products
1.14 Sector Challenges
1.15 Regulatory, Cost Effectiveness and Clinical
1.15.2 Cost Effectiveness
1.16 Competition Intensity
1.16.1 Industry Focus
1.16.2 Investment Levels
1.16.3 Investor Returns
2.2 Cardiovascular Tissue Transplantation and Engineering
2.2.2 Coronary Heart Disease
2.2.3 Myocardial Infarction
2.2.4 Congestive Heart Failure
2.2.5 Dysfunctional Heart Valves
2.2.6 Peripheral Vascular Disorders
2.2.7 Abdominal Aortic Aneurysms
2.2.8 Drivers of Caseloads for Cardiac Tissue Engineering
2.3 Neurological Tissue Transplantation and Engineering
2.3.6 Traumatic Injury
2.3.7 Peripheral Nerve Treatment
2.3.8 Multiple Sclerosis
2.3.9 Neurology Drivers
2.4 Orthopedic Tissue Transplantation and Engineering
2.4.2 Cartilage Repair
2.4.3 Ligament Damage
2.4.4 Other Joints
2.4.5 Bone Graft Materials
2.4.6 Vertebral Disc Repair
2.4.7 Drivers of Orthopedic Tissue Engineering
2.5 Urological Tissue Transplantation and Engineering
2.5.3 Drivers of Urological Tissue Engineering
2.6 Skin Tissue Transplantation and Engineering
2.6.3 Diabetic Ulcers
2.6.4 Venous Ulcers
2.6.5 Plastic Surgery
2.7 Organ Transplantation and Engineering
2.7.2 Liver Disease
2.7.5 Intestinal Tissue Engineering
2.7.6 Hematopoietic Tissue Engineering
2.7.7 Drivers of Organ Replacement Tissue Engineering
Technologies, Products and Markets
3.6 Skin Cell Engineering
3.8 Organ Reconstruction and Replacement
3.9 Potential for ‘Tissue Engineering’ Reconstruction
Aastrom Bioscience Inc.
Advanced Medical Solutions PLC
Acorda Therapeutics Inc.
Advanced Cell Technology
Advanced Tissue Sciences Inc.
Ariad Pharmaceuticals Inc.
Anthrogenesis Inc. (Celgene Corp.)
Baxter International Inc.
Biovascular Inc. (Synovis Life Technologies Inc.)
Biolife Solutions Inc.
Bionx Implants, Inc. (CONMED Corporation)
Cardiotech International Inc.
Based Delivery Inc.
Science Therapeutics Inc.
Cellect Bio Inc.
Celmed BioSciences Inc. (Theratechnologies)
Chrysalis BioTechnolology, Inc.
Circe Biomedical Inc.
Clinical Cell Culture (C3)
Cytograft Tissue Engineering
Cell International Pte Ltd
Enact Pharma PLC
Excorp Medical, Inc.
Fidia Advanced Biomaterials
Genetix Pharmaceuticals Inc.
Genzyme Molecular Oncology
Instrument Makar Inc.
Integra Life Sciences Inc.
Interface Biologics Inc.
Intermountain Organ Recovery Service
Interpore Cross International Inc.
Islet Sheet Medical
Islet Technology, Inc.
Ixion Biotechnology Inc.
Johnson and Johnson Inc. (Ethicon, DePuy, Mitek)
Kourion Therapeutics AG
Layton Biosciences Inc.
Medical Sciences Inc.
Linvatec Corporation Inc.
Macropore Biosurgery Inc.
Millenium Biologix Inc.
MorphoGen Pharmaceuticals Inc.
Musculoskeletal Transplant Foundation
Nephros Therapeutics Inc.
NeuralStem Biopharmaceuticals Inc
Neurotech SA and Neurotech U.S. Inc.
Organ Recovery Systems
Ortec International Inc.
Osiris Therapeutics Inc.
Protein Polymer Technologies Inc.
Progenitor Cell Therapy Inc.
ProNeuron Biotechnologies, Inc.
Regen Biologics Inc.
Regeneration Technologies Inc.
Renaissance Cell Technologies
Select Therapeutics Inc.
Sertoli Technologies Inc.
Smith and Nephew Ltd
Cell Pharmaceuticals Inc.
Cell Sciences Ltd UK
Cell Sciences Ltd
StemCell Technologies Inc.
Surgical Dynamics Inc.
Synovis Life Technologies, Inc.
Targeted Genetics Inc.
Tissue Transformation Technologies Inc.
Tissue Therapeutics, Inc.
Titan Pharmaceuticals Inc.
Transition Therapeutics Inc
Triage Medical Inc.
Xcyte Therapies, Inc.
Appendix: List of Companies
List of Exhibits
Exhibit 1-1: Corporate Involvement in Tissue Transplantation and
Exhibit 1-2: Worldwide Market for Material Based Tissue
Reconstruction Products, 2001–2013
Exhibit 1-3: Select Companies Developing Materials Applicable to
Material-Based Tissue Reconstruction
Exhibit 1-4: Worldwide Sales of Tissue Engineered Products, 2002
Exhibit 1-5: Worldwide Sales of Donor Tissue Products, 2001-2013
Exhibit 1-6: Worldwide Market for Tissue Engineered Products,
Exhibit 1-7: Timescales for Development of Tissue Engineered
Exhibit 1-8: Clinical Development and Approvals (U.S.)
Exhibit 1-9: Examples of Tissue Engineering Strategies
Exhibit 1-10: Annual Revenues from Cell-Based Tissue Engineering
Ventures in 2002
Exhibit 2-1: Potential For Cardiovascular Tissue Engineering —
Incidences of Applicable Surgical Procedures, 2002
Exhibit 2-2: Potential for Neurological Tissue Engineering —
Incidences of Applicable Procedures, 2002
Exhibit 2-3: Potential for Orthopedic Tissue Engineering —
Incidence of Applicable Procedures, 2002
Exhibit 2-4: Potential for Urological Tissue Engineering —
Incidence of Applicable Procedures, 2002
Exhibit 2-5: Potential for Dermal Tissue Engineering — Incidence
of Applicable Procedures, 2002
Exhibit 2-6: Potential for Organ Tissue Engineering — Incidence
of Applicable Procedures, 2002
Exhibit 3-1: Cardiovascular Cell Engineering Companies —
Exhibit 3-2: Key Developments for Cardiovascular Repair
Exhibit 3-3: Neurological Cell Engineering Companies —
Exhibit 3-4: Key Developments in Neurological Repair
Exhibit 3-5: Orthopedic Cell Engineering Companies — Timescales
Exhibit 3-6: Key Developments in Orthopedic Repair
Exhibit 3-7: Urology Cell Engineering Companies — Timescales
Exhibit 3-8: Key Developments in Urological Tissue Engineering
Exhibit 3-9: Skin Cell Engineering Companies — Timescales
Exhibit 3-10: Key Developments in Skin Tissue Engineering
Exhibit 3-11: Hematopoietic Cell Engineering Companies -
Exhibit 3-12: Key Developments in Hematopoietic Tissue
Exhibit 3-13: Organ Cell Engineering Companies — Timescales
Exhibit 3-14: Key Developments in Organ Tissue Engineering
Exhibit 3-15: Worldwide Market for Tissue Engineered Products,